Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q4 FY2026 Earnings Presentation
18 slides from Dr. Reddy's Laboratories's earnings presentation, May 12, 2026
Slide 1: Regulation 30 Intimation – Q4 and FY26 Audited Financial Results Presentation
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com May 12, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE
Slide 2: Q4 & FY26 Results Update
Dr. Reddy’s Q4 & FY26 RESULTS UPDATE 12 MAY 2026 1 | September 2025 | Investor Presentation | As per consolidated financial statements under IFRS
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 4: Q4FY26 Financial Highlights
Q4FY26 Financial Highlights Double-digit growth in base business^ and 19.5% EBITDA Margin before impact of specific items Reported Revenues ₹ 7,516 Cr FINANCIALS EXCLUDING SPECIFIC ITEMS 12%YoY 14%QoQ Financials excluding specific items EBITDA | EBITDA % 7,969 48.0% 19.5% 12.5% ₹ 981 Cr | 13% Provis
Slide 5: FY26 Financial Highlights
FY26 Financial Highlights Performance aided by double-digit base business^ growth, acquired NRT business & productivity efforts before impact of specific items Reported Revenues ₹ 33,593 Cr FINANCIALS EXCLUDING SPECIFIC ITEMS 3%YoY Financials excluding specific items EBITDA | EBITDA % 34,046 53.5% 2
Slide 6: Q4FY26 Business Highlights
Q4FY26 Business Highlights Steady progress across strategic priorities • Dr. Reddy’s becomes 1st company to secure approval for generic semaglutide injection for Type 2 Diabetes in Canada • Day 1 launch of generic semaglutide injection under brand name, ‘Obeda®’ in India. • Secured approval from DCG
Slide 7: Other Highlights
Q4FY26 Other Highlights ESG • Gold Medal by EcoVadis for FY26, achieving our highest-ever score of 80, placing us among top 5% companies assessed globally. • Among India’s Top 5 Most Sustainable Companies by BusinessWorld, #1 in Indian healthcare & pharmaceutical industry for 2024-25. • ‘Leadership
Slide 8: Q4FY26 Revenue Split
Q4FY26 Revenue Split Broad-based growth ex. US, supported by forex; moderated by lower lenalidomide sales and SSA REVENUE BY SEGMENT GLOBAL GENERICS SPLIT North America Europe GLOBAL GENERICS ₹ 1,756 Cr ₹ 1,452 Cr 88% 51%YoY 41%QoQ 14%YoY 0.3%QoQ Overall* 19% ₹ 7,516 Cr 23% 12% 14% YoY QoQ PSAI 12%
Slide 9: FY26 Revenue Split
FY26 Revenue Split Double digit growth across geographies, except North America due to product-specific headwinds REVENUE BY SEGMENT GLOBAL GENERICS SPLIT North America Europe GLOBAL GENERICS ₹ 11,374 Cr ₹ 5,550 Cr 89% 22%YoY 55%YoY* Overall* 17% 34% ₹ 33,593 Cr 3%YoY PSAI 10% 19% India OTHERS 1% ₹
Slide 10: Key Financial Metrics
Key Financial Metrics Sustaining growth & profitability, while investing for the future REVENUES GROSS MARGINS SG&A R&D EBITDA MARGINS (₹ Cr) (% of Revenues) (% of Revenues) (% of Revenues) (% of Revenues) *Q4FY26 7,516 *Q4FY26 44.8% *Q4FY26 36.9% *Q4FY26 7.3% *Q4FY26 13.0% Q3FY26 8,727 Q3FY26 53.6%
Slide 11: North America Performance
Q4FY26 North America Performance Impacted by lower sales and shelf stock adjustment of lenalidomide MARKET PERFORMANCE KEY UPDATES 23% 7.6% VS 0.8% • First company to secure approval for generic semaglutide injection for DRL Growth vs US Generics Market (Excl. Lenalidomide) *As per IQVIA MAT Feb’ 26
Slide 12: Emerging Markets Performance
Q4FY26 Emerging Markets Performance New product launches, higher volume uptake and favourable forex driving growth KEY UPDATES 24% COUNTRIES PRESENT IN • Launched Tegoprazan in Russia 48 • Submitted responses to ANVISA in Brazil to address concerns w.r.t. NEW PRODUCT LAUNCHES our generic Semaglutide
Slide 13: India Performance
Q4FY26 India Performance Sustained double-digit growth, continued outperformance of IPM MARKET PERFORMANCE* KEY UPDATES 21% 15.2% VS 11.6% *DRL MQT Growth vs IPM (Mar’26) • Day 1 launch of generic semaglutide injection under brand name, ‘Obeda®’. IPM RANK #9 #10 • Secured approval from DCGI for gene
Slide 14: Europe Performance
Q4FY26 Europe Performance Momentum in new launches, aided by forex tailwinds, moderated by pricing pressure 19% KEY UPDATES EU COUNTRIES PRESENT IN • NRT integration progressing well; 95% business value integrated. 20 Revenues REVENUE SPLIT ₹ 1,452 Cr NEW GX PRODUCT NRT ₹ 696 Cr LAUNCHES 14%YoY 0.3%
Slide 15: PSAI Performance
Q4FY26 PSAI Performance Decline on account of lower API volume uptake KEY UPDATES 12% GROSS MARGIN • CDMO business under subsidiary, Aurigene Pharmaceutical Services Limited continues to see good traction 19.9% VS 26.3% Q4FY26 vs Q4FY25 Revenues • Multiple collaboration opportunities through PSAI. ₹
Slide 16: In Summary
In Summary A diversified business model with broad based levers Strengthen Core Businesses, build future growth drivers (Peptides, Biosimilars, Consumer Health, Innovation) Advance key pipeline products (Semaglutide, Abatacept) Drive efficiencies through better operational leverage The picture can't
Slide 17: About Key Metrics and Non-GAAP Financial Measures
About Key Metrics and Non-GAAP Financial Measures This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non- GAAP financial measures are measures of our historical performance, financial position or cash flows that are
Slide 18: Good Health Can't Wait.
Good Health Can’t Wait. 17 | September 2025 | Investor Presentation | As per consolidated financial statements under IFRS
Dr. Reddy's Laboratories — Q4 FY2026 Earnings Presentation on 6ix